The first and only therapy that is designed to correct the underlying immune defect in APDS1-4
APDS, activated PI3Kδ syndrome.
Joenja is the first and only FDA-approved
therapy indicated for the treatment
of APDS. Joenja helps address both immune
deficiency AND immune dysregulation.5
Joenja demonstrated significant efficacy
and safety tolerability in a Phase 3,
randomized controlled clinical trial.1
Access & Patient Support
Obtain information regarding access to
Joenja, the APDS Assist program, and other
helpful resources for your patients with
APDS is a rare, primary immunodeficiency.
Hyperactivity along the PI3Kδ signaling
pathway disrupts immune cell balance,
causing immune deficiency and
Your resource for clinical developments and important information regarding APDS and Joenja.
Help your patients with APDS remember every dose with the free Joenja reminder tone.